Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
S&P 500 rises, Nasdaq jumps 2% in recovery rally after Nvidia-led sell-off: Live updates
The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...
Hosted on MSN11h
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
AbbVie price target lowered to $205 from $215 at Citi
Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...
Bristol Myers price target raised to $65 from $60 at Citi
Citi raised the firm’s price target on Bristol Myers (BMY) to $65 from $60 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, ...
Trump order set to halt supply of HIV, malaria drugs to poor countries, sources say
The Trump administration has moved to stop the supply of lifesaving drugs for HIV, malaria and tuberculosis, as well as ...
Eli Lilly's SWOT analysis: stock poised for growth amid challenges
Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...